In clinical settings, elevated pre-procedural chemerin, together with insulin resistance, independently predicted the risk of post-ERCP pancreatitis [42], suggesting that endogenous chemerin elevation reflects metabolic-inflammatory susceptibility, likely driven by adipose-derived inflammation. Here, RARRES2 is linked to pancreatitis.